Trimetazidine
Based on 18 publication(s) in Google Scholar
Trimetazidine is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC50 of 75 nM, which can inhibit β-oxidation of free fatty acid (FFA). Trimetazidine is an effective antianginal agent and a cytoprotective agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine triggers autophagy. Trimetazidine is also a 3-hydroxyacyl-CoA dehydrogenase (HADHA) inhibitor.
For research use only. We do not sell to patients.
- Purity: 99.84%
- CAS No.: 5011-34-7
- Formula: C14H22N2O3
- Molecular Weight:266.34
-
Storage:
4°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
FDA-Approved Drug Library
HY-L022
-
Autophagy Compound Library
HY-L029
-
Drug Repurposing Compound Library
HY-L035
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
NMPA-Approved Drug Library
HY-L053
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Rare Diseases Drug Library
HY-L102
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Mitochondrial Toxicity Compound Library
HY-L155
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Drug Fragment Library
HY-L904
Publications Citing Use of MedChemExpress (MCE) Trimetazidine
More- Nat Metab. 2025 Jan;7(1):84-101. [Abstract]
- Mol Cell. 2020 Oct 1;80(1):43-58.e7. [Abstract]
- Adv Sci (Weinh). 2026 Jan 21:e17054. [Abstract]
- Adv Sci (Weinh). 2025 May 14:e2416419. [Abstract]
- J Adv Res. 2025 Mar 17:S2090-1232(25)00186-9. [Abstract]
- Sci Adv. 2025 Aug 29;11(35):eadu6271. [Abstract]
- Acta Pharmacol Sin. 2022 Oct;43(10):2550-2561. [Abstract]
- Cell Rep. 2024 Aug 7;43(8):114591. [Abstract]
- ACS Appl Nano Mater. 2025 Jun 9;8(24).
- J Ethnopharmacol. 2026 Mar 1:358:121033. [Abstract]
- J Ethnopharmacol. 2026 Feb 28:357:120899. [Abstract]
- J Pathol. 2026 Jan;268(1):99-112. [Abstract]
- Front Biosci (Landmark Ed). 2025 Jan 20;30(1):25565. [Abstract]
- J Pharm Biomed Anal. 2021 Feb 20:195:113870. [Abstract]
- Anatol J Cardiol. 2019 Nov;22(5):232-239. [Abstract]
- University of California, Irvine. 2026.
- bioRxiv. 2025 April 10.
- Wiad Lek. 2025;78(1):35-44. [Abstract]
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Cell Migration/Invasion Assay
-
Cell Migration/Invasion Assay
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
Biological Activity
IC50: 75 nM (long chain 3-ketoyl coenzyme A thiolase)[2]
β-oxidation[2]
Autophagy[3]
3-hydroxyacyl-CoA dehydrogenase (HADHA)[4]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| KB | IC50 |
47.1 μM
Compound: 43
|
Cytotoxicity in human KB cells
Cytotoxicity in human KB cells
|
[PMID: 21504156] |
Trimetazidine (1-100 μM; 24 hours; HUVECs) could enhance the viability of the injured HUVECs induced by oxidation in a certain dose-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human umbilical vein endothelial cells (HUVECs)
-
Concentration:1 μM,10 μM,100 μM
-
Incubation Time:24 hours
-
Result:Enhanced the viability of the injured HUVECs induced by oxidation.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Swiss albino male mice (24-35 g)[4]
-
Dosage:5 mg/kg, 10 mg/kg and 20 mg/kg;
10 mL/kg body weight -
Administration:Oral administration ; 1 hour
-
Result:In 10 and 20mg/kg doses significantly raised the seizure-threshold current in the ICES test.
Chemical Information
-
CAS No. 5011-34-7
-
Appearance Oil
-
Molecular Weight 266.34
-
Formula C14H22N2O3
-
Color White to off-white
-
SMILES
COC1=CC=C(CN2CCNCC2)C(OC)=C1OC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Publications (18)
-
Journal Impact Factor
-
Most Recent
-
Nat Metab
2025 Jan;7(1):84-101. PMID: 39747484 -
Mol Cell
Histone Deacetylase 3 Couples Mitochondria to Drive IL-1β-Dependent Inflammation by Configuring Fatty Acid Oxidation. [Abstract]2020 Oct 1;80(1):43-58.e7. PMID: 32937100 -
Adv Sci (Weinh)
OCTN2 Activates a Non-Canonical Carnitine Metabolic Pathway to Promote MASH-HCC Progression and Immunotherapy Resistance. [Abstract]2026 Jan 21:e17054. PMID: 41566533
Trimetazidine purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2026 Jan 21:e17054. [Abstract]
Colony formation assays evaluated the proliferative capacity of MASH‐HCC cells (PA/OA and IL-6/TNF-α/LPS-treated HuH‐7 cells) and non-MASH-HCC cells transfected with vector or OCTN2, with or without Trimetazidine (TMZ) (1 mM).
Trimetazidine purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2026 Jan 21:e17054. [Abstract]
The FAO inhibitor Trimetazidine (TMZ) (1 mM) abrogated the enhanced migration and invasion of non-MASH-HCC cells caused by OCTN2 overexpression.
Trimetazidine purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2026 Jan 21:e17054. [Abstract]
Wound healing assays evaluated the migration ability of MASH-HCC and non-MASH-HCC cells transfected with vector or OCTN2, with or without Trimetazidine (TMZ) (1 mM) treatment.
-
Adv Sci (Weinh)
MTFR2-Mediated Fission Drives Fatty Acid and Mitochondrial Co-Transfer from Hepatic Stellate Cells to Tumor Cells Fueling Oncogenesis. [Abstract]2025 May 14:e2416419. PMID: 40365837 -
J Adv Res
Mitochondrial fatty acid oxidation as the target for blocking therapy-resistance and inhibiting tumor recurrence: The proof-of-principle model demonstrated for ovarian cancer cells. [Abstract]2025 Mar 17:S2090-1232(25)00186-9. PMID: 40107354
Trimetazidine purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Mar 17:S2090-1232(25)00186-9. [Abstract]
OVCAR8-Persister and A2780-Persister cells were pretreated with vehicle or Trimetazidine (TMZ) (100 μM; 24 h) and subsequently treated with various concentrations of paclitaxel (1-1×104 nM; 48 h), after which cell viability was assessed using a CCK-8 assay.
Trimetazidine purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Mar 17:S2090-1232(25)00186-9. [Abstract]
Trimetazidine (TMZ) (100 μM; 24 h) pretreatment increased the sensitivity of OVCAR8-Persister and A2780-Persister cells to paclitaxel.
-
Sci Adv
Glutamate utilization fuels rapid production of mitochondrial ROS in dendritic cells and drives systemic inflammation during tularemia. [Abstract]2025 Aug 29;11(35):eadu6271. PMID: 40880474 -
Acta Pharmacol Sin
Trimetazidine enhances myocardial angiogenesis in pressure overload-induced cardiac hypertrophy mice through directly activating Akt and promoting the binding of HSF1 to VEGF-A promoter. [Abstract]2022 Oct;43(10):2550-2561. PMID: 35217815 -
Cell Rep
2024 Aug 7;43(8):114591. PMID: 39116204 -
-
J Ethnopharmacol
Qiang-Xin 1 formula improves cardiac function and alleviates myocardial injury in lipopolysaccharide-induced septic mice by activating calcium/calmodulin-dependent protein kinase I-mediated mitophagy. [Abstract]2026 Mar 1:358:121033. PMID: 41397542 -
J Ethnopharmacol
Integrating UPLC-Q-TOF-MS/MS, feature-based molecular networking, network pharmacology, and molecular docking to investigate the mechanism of Persicae Ramulus against myocardial ischemia. [Abstract]2026 Feb 28:357:120899. PMID: 41241210 -
J Pathol
Hypoxia-induced regional heterogeneity in proliferative vitreoretinopathy: implications for targeted therapies. [Abstract]2026 Jan;268(1):99-112. PMID: 41215615 -
Front Biosci (Landmark Ed)
Trimetazidine: Activating AMPK Signal to Ameliorate Coronary Microcirculation Dysfunction after Myocardial Infarction. [Abstract]2025 Jan 20;30(1):25565. PMID: 39862078 -
J Pharm Biomed Anal
Screening method of mildronate and over 300 doping agents by reversed-phase liquid chromatography-high resolution mass spectrometry. [Abstract]2021 Feb 20:195:113870. PMID: 33453569 -
Anatol J Cardiol
Protective effects of trimetazidine and coenzyme Q10 on cisplatin-induced cardiotoxicity by alleviating oxidative stress and mitochondrial dysfunction. [Abstract]2019 Nov;22(5):232-239. PMID: 31674935 -
-
-
Wiad Lek
Potential cardioprotective effect of trimetazidine in mice model of endotoxemia: role of AMPK-Nrf2. [Abstract]2025;78(1):35-44. PMID: 40023854
Solvent & Solubility
DMSO : 116.67 mg/mL (438.05 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (7.81 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (7.81 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (477 KB)
- English - EN (477 KB)
- Français - FR (477 KB)
- Deutsch - DE (477 KB)
- Norwegian - NO (477 KB)
- Español - ES (477 KB)
- Swedish - SV (477 KB)
- Italian - IT (477 KB)
- Portuguese - PT (477 KB)
-
Handling Instructions (2659 KB)
References
[2]. Chrusciel P, et al. Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease. Drugs. 2014 Jun;74(9):971-80. [Content Brief]
[3]. Kantor PF, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000 Mar 17;86(5):580-8. [Content Brief]
[4]. Hossain F, et al.Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies. Cancer Immunol Res. 2015 Nov;3(11):1236-47. [Content Brief]
[5]. Jain S, et al. Trimetazidine exerts protection against increasing current electroshock seizure test in mice. Seizure. 2010 Jun;19(5):300-2. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.7546 mL | 18.7730 mL | 37.5460 mL | 93.8650 mL |
| 5 mM | 0.7509 mL | 3.7546 mL | 7.5092 mL | 18.7730 mL | |
| 10 mM | 0.3755 mL | 1.8773 mL | 3.7546 mL | 9.3865 mL | |
| 15 mM | 0.2503 mL | 1.2515 mL | 2.5031 mL | 6.2577 mL | |
| 20 mM | 0.1877 mL | 0.9386 mL | 1.8773 mL | 4.6932 mL | |
| 25 mM | 0.1502 mL | 0.7509 mL | 1.5018 mL | 3.7546 mL | |
| 30 mM | 0.1252 mL | 0.6258 mL | 1.2515 mL | 3.1288 mL | |
| 40 mM | 0.0939 mL | 0.4693 mL | 0.9386 mL | 2.3466 mL | |
| 50 mM | 0.0751 mL | 0.3755 mL | 0.7509 mL | 1.8773 mL | |
| 60 mM | 0.0626 mL | 0.3129 mL | 0.6258 mL | 1.5644 mL | |
| 80 mM | 0.0469 mL | 0.2347 mL | 0.4693 mL | 1.1733 mL | |
| 100 mM | 0.0375 mL | 0.1877 mL | 0.3755 mL | 0.9386 mL |
Powered by Bioz